Pegmusirudin
Script error: No such module "Draft topics".
Script error: No such module "AfC topic".
Pegmusirudin is a pharmaceutical drug that is being developed as an anticoagulant for treatment of thromboembolic disorders such as deep vein thrombosis and pulmonary embolism.[1] It is designed to selectively inhibit Factor IXa, a protein involved in the coagulation pathway.[2] By targeting Factor IXa, pegmusirudin helps prevent the formation of blood clots, which can lead to serious health complications if left untreated. Clinical trials are ongoing to evaluate the safety and efficacy of pegmusirudin in various patient populations.
References[edit]
- ↑ Gómez-Outes, Antonio; Suárez-Gea, Maria Luisa; Lecumberri, Ramón; Rocha, Eduardo; Pozo-Hernández, Carmen; Vargas-Castrillón, Emilio (2011). "New parenteral anticoagulants in development". Therapeutic Advances in Cardiovascular Disease. 5 (1): 33–59. doi:10.1177/1753944710387808. ISSN 1753-9447.
- ↑ Chaudhry, Raheel; Usama, Syed Muhammad; Babiker, Hani M. (2023), "Physiology, Coagulation Pathways", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 29489185, retrieved 2023-07-23
 | This pharmacology-related article is a stub. You can help EverybodyWiki by expanding it. |
This article "Pegmusirudin" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Pegmusirudin. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
